The AIM-listed firm said a mask manufacturing machine arrived as expected and has been installed in a cleanroom in Nottingham’s BioCity, with work to begin this week to commission the device and commence production.
READ: Remote Monitored Systems appoints two new non-executive directors, with one named company's new chairman
Remote Monitored Systems said the last element prior to full-scale production of its 4-ply mask is its certification to EN14683 standard, for which the product has now passed four of five tests.
The final test is biocompatibility, which evaluates the reaction to human skin including cytotoxicity, irritation and sensitisation to the mask. The company said the test has been delayed and is now expected to be completed in the next week.
Assuming the commissioning proceeds as expected, Remote Monitored Systems said it is working towards producing between 0.3mln and 0.5mln masks by the end of January before scaling up production to commercial levels in February and March.
The company added that discussions are also continuing with Volz Group, which needs to conclude its own certification process, for it to manufacture both a surgical mask and FFP2 masks, although production is not expected to commence much before the end of the first quarter.
Remote Monitored Systems also said that while the move to production is “a positive step”, the success of the operation will be demonstrated by securing sales orders, and that while interest remains strong it has yet to receive firm orders with certification of the mask an “important step” for potential customers.
Meanwhile, the company said it has appointed Alex Vergopoulos as an executive director with an initial responsibility to oversee the production and sales of the viricidal surgical masks.
The firm's shares were 9.4% lower at 2.7p in late-morning trading on Monday.
--Adds share price--